PDF factsheet
      Z

combination chemotherapy with platinum salts in advanced breast cancer (metastatic) for all type of patients, clinical trials results

CAP versus CFP
Creagan ET, 1984
four cycles of cyclophosphamide, Adriamycin (Adria Laboratories, Inc, Columbus, Ohio), cisplatin (CAP) followed by maintenance with cyclophosphamide, 5-fluorouracil, prednisone (CFP)
versus
CAP versus CMFVP
Kolaric, 1985

versus
CAP versus FAC
Kolaric, 1989

versus
carboplatin followed by CAF versus CAF
Costanza, 1999
carboplatin followed by CAF
versus
immediate chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF)
women with measurable metastatic breast cancer, previously untreated with chemotherapy for their metastatic disease
cisplatin + epirubicin versus lonidamine + epirubicin
Berruti A, 2002
cisplatin + epirubicin
versus
lonidamine + epirubicin
Berruti B, 2002

versus
cisplatin + etoposide versus CMF
Cocconi, 1991
cisplatin (P) and etoposide (E)
versus
standard cyclophosphamide, methotrexate, and fluorouracil (CMF)
CMF, cisplatin, etoposide, and doxorubicin versus CMF
Cocconi, 1999
The same single agents (C, M, F, cisplatin, etoposide, and doxorubicin) were administered in both experimental arms, but following a different policy.
versus
cyclophosphamide, methotrexate, and 5-fluorouracil
EcisF versus ECycloF
Eisen, 1998

versus
EPI + CIS versus EPI
Nielsen, 2000

versus
MPEPIV or MPEMi versus CMF
Cocconi G, 1996

versus
PCb versus PE
Fountzilas, 2002

versus
VP-16+P versus paclitaxel
Icli, 2002

versus

  Options


in first

in second

  Filter